Betamethasone Valerate | CAS#2152-44-5 | Potent glucocorticoid

MedKoo Cat#: 317319 | Name: Betamethasone Valerate

Featured

Description:

WARNING: This product is for research use only, not for human or veterinary use.

Betamethasone Valerate is the 17-valerate derivative of Betamethasone. Betamethasone Valerate acts as a moderately potent glucocorticoid steroid with anti-inflammatory and immunosuppressive properties. Betamethasone valerate binds to specific intracellular glucocorticoid receptors and subsequently binds to DNA to modify gene expression. The synthesis of certain anti-inflammatory proteins is induced while the synthesis of certain inflammatory mediators is inhibited.

Chemical Structure

Betamethasone Valerate

CAS#2152-44-5 (valerate)

Theoretical Analysis

MedKoo Cat#: 317319

Name: Betamethasone Valerate

CAS#: 2152-44-5 (valerate)

Chemical Formula: C27H37FO6

Exact Mass: 476.2574

Molecular Weight: 476.59

Elemental Analysis: C, 68.05; H, 7.83; F, 3.99; O, 20.14

Price and Availability

Size	Price	Availability
50mg	USD 350.00	2 Weeks
100mg	USD 550.00	2 weeks
200mg	USD 750.00	2 weeks
500mg	USD 950.00	2 weeks
1g	USD 1,450.00	2 weeks

Bulk Inquiry

Buy Now

Add to Cart

Related CAS #

378-44-9 (free acid) 5534-05-4 (acibutate) 987-24-6 (acetate) 5593-20-4 (dipropionate) 151-73-5 (sodium phosphate) 2152-44-5 (valerate) 22298-29-9 (benzoate)

Synonym

Betamethasone Valerate; Betoid; Valison; 9α-Fluo; Valisone; Bedermin; Betneval; Beta-Val; Bextasol; Dermosol; Stanoval

IUPAC/Chemical Name

(8S,9R,10S,11S,13S,14S,16S,17R)-9-fluoro-11-hydroxy-17-(2-hydroxyacetyl)-10,13,16-trimethyl-3-oxo-6,7,8,9,10,11,12,13,14,15,16,17-dodecahydro-3H-cyclopenta[a]phenanthren-17-yl pentanoate

InChi Key

SNHRLVCMMWUAJD-SUYDQAKGSA-N

InChi Code

InChI=1S/C27H37FO6/c1-5-6-7-23(33)34-27(22(32)15-29)16(2)12-20-19-9-8-17-13-18(30)10-11-24(17,3)26(19,28)21(31)14-25(20,27)4/h10-11,13,16,19-21,29,31H,5-9,12,14-15H2,1-4H3/t16-,19-,20-,21-,24-,25-,26-,27-/m0/s1

SMILES Code

O=C1C=C[C@@]2([C@]3([C@H](C[C@@]4([C@](OC(CCCC)=O)([C@H](C[C@]4([C@@]3(CCC2=C1)[H])[H])C)C(CO)=O)C)O)F)C

Appearance

Solid powder

Purity

>98% (or refer to the Certificate of Analysis)

Shipping Condition

Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition

Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).

Solubility

Soluble in DMSO, not in water

Shelf Life

>2 years if stored properly

Drug Formulation

This drug may be formulated in DMSO

Stock Solution Storage

0 - 4 C for short term (days to weeks), or -20 C for long term (months).

HS Tariff Code

2934.99.9001

More Info

Certificate of Analysis

View CoA: current batch, Lot#C21M07C02

Safety Data Sheet (SDS)

View Safety Data Sheet (SDS)

Instruction

View handling instruction

	Solvent	mg/mL	mM
Solubility
	DMF	25.0	52.46
	DMSO	75.0	157.37
	DMSO:PBS (pH 7.2) (1:10)	0.1	0.21
	Ethanol	30.5	64.00

Note: There can be variations in solubility for the same chemical from different vendors or different batches from the same vendor. The following factors can affect the solubility of the same chemical: solvent used for crystallization, residual solvent content, polymorphism, salt versus free form, degree of hydration, solvent temperature. Please use the solubility data as a reference only. Warming and sonication will facilitate dissolving. Still have questions? Please contact our Technical Support scientists.

Preparing Stock Solutions

The following data is based on the product molecular weight 476.59 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Concentration / Solvent Volume / Mass	1 mg	5 mg	10 mg
1 mM	1.15 mL	5.76 mL	11.51 mL
5 mM	0.23 mL	1.15 mL	2.3 mL
10 mM	0.12 mL	0.58 mL	1.15 mL
50 mM	0.02 mL	0.12 mL	0.23 mL

1: Maccari F. Improvement of inflammatory dermatoses severity and quality of life in patients treated with a betamethasone valerate plaster (LIBERE study). J Dermatolog Treat. 2015 Jun 15:1-5. [Epub ahead of print] PubMed PMID: 25898980. 2: Lotfy HM, Salem H, Abdelkawy M, Samir A. Spectrophotometric methods for simultaneous determination of betamethasone valerate and fusidic acid in their binary mixture. Spectrochim Acta A Mol Biomol Spectrosc. 2015 Apr 5;140:294-304. doi: 10.1016/j.saa.2014.12.059. Epub 2015 Jan 9. PubMed PMID: 25615682. 3: Chittock J, Brown K, Cork MJ, Danby SG. Comparing the Effect of a Twice-weekly Tacrolimus and Betamethasone Valerate Dose on the Subclinical Epidermal Barrier Defect in Atopic Dermatitis. Acta Derm Venereol. 2015 Jun 24;95(6):653-8. doi: 10.2340/00015555-2048. PubMed PMID: 25594610. 4: Danby SG, Chittock J, Brown K, Albenali LH, Cork MJ. The effect of tacrolimus compared with betamethasone valerate on the skin barrier in volunteers with quiescent atopic dermatitis. Br J Dermatol. 2014 Apr;170(4):914-21. doi: 10.1111/bjd.12778. PubMed PMID: 24328907. 5: Ortonne JP, Esposito M, Chimenti S, Kapińska-Mrowiecka M, Grodzińska A, Naldi L, Frangione V. Betamethasone valerate dressing is non-inferior to calcipotriol-betamethasone dipropionate ointment in the treatment of patients with mild-to-moderate chronic plaque psoriasis: results of a randomized assessor-blinded multicentre trial. J Eur Acad Dermatol Venereol. 2014 Sep;28(9):1226-34. doi: 10.1111/jdv.12270. Epub 2013 Oct 29. PubMed PMID: 24256460; PubMed Central PMCID: PMC4282443. 6: Deo KS, Dash KN, Sharma YK, Virmani NC, Oberai C. Kojic Acid vis-a-vis its Combinations with Hydroquinone and Betamethasone Valerate in Melasma: A Randomized, Single Blind, Comparative Study of Efficacy and Safety. Indian J Dermatol. 2013 Jul;58(4):281-5. doi: 10.4103/0019-5154.113940. PubMed PMID: 23918998; PubMed Central PMCID: PMC3726874. 7: Pratap DV, Philip M, Rao NT, Jerajani HR, Kumar SA, Kuruvila M, Moodahadu LS, Dhawan S. Evaluation of Efficacy, Safety, and Tolerability of Fixed Dose Combination (FDC) of Halometasone 0.05% and Fusidic Acid 2% W/W Topical Cream Versus FDC of Betamethasone Valerate 0.12% and Neomycin Sulphate 0.5% W/W Topical Cream in the Treatment of Infected Eczematous Dermatosis in Indian Subjects: A Randomized Open-Label Comparative Phase III Multi-Centric Trial. Indian J Dermatol. 2013 Mar;58(2):117-23. doi: 10.4103/0019-5154.108041. PubMed PMID: 23716800; PubMed Central PMCID: PMC3657210. 8: Özcan I, Azizoğlu E, Senyiğit T, Özyazici M, Özer Ö. Comparison of PLGA and lecithin/chitosan nanoparticles for dermal targeting of betamethasone valerate. J Drug Target. 2013 Jul;21(6):542-50. doi: 10.3109/1061186X.2013.769106. Epub 2013 Feb 8. PubMed PMID: 23390922. 9: Khattak SU, Sheikh D, Ahmad I, Usmanghani K. Kinetics of thermal degradation of betamethasone valerate and betamethasone dipropionate in different media. Indian J Pharm Sci. 2012 Mar;74(2):133-40. doi: 10.4103/0250-474X.103845. PubMed PMID: 23325994; PubMed Central PMCID: PMC3546330. 10: Sookpotarom P, Asawutmangkul C, Srinithiwat B, Leethochawalit S, Vejchapipat P. Is half strength of 0.05 % betamethasone valerate cream still effective in the treatment of phimosis in young children? Pediatr Surg Int. 2013 Apr;29(4):393-6. doi: 10.1007/s00383-012-3253-9. PubMed PMID: 23292538. 11: Uaboonkul T, Nakakes A, Ayuthaya PK. A randomized control study of the prevention of hyperpigmentation post Q-switched Nd:YAG laser treatment of Hori nevus using topical fucidic acid plus betamethasone valerate cream versus fucidic acid cream. J Cosmet Laser Ther. 2012 Jun;14(3):145-9. doi: 10.3109/14764172.2012.682066. PubMed PMID: 22471899. 12: Kuldeep C, Singhal H, Khare AK, Mittal A, Gupta LK, Garg A. Randomized comparison of topical betamethasone valerate foam, intralesional triamcinolone acetonide and tacrolimus ointment in management of localized alopecia areata. Int J Trichology. 2011 Jan;3(1):20-4. doi: 10.4103/0974-7753.82123. PubMed PMID: 21769231; PubMed Central PMCID: PMC3129118. 13: Naldi L, Yawalkar N, Kaszuba A, Ortonne JP, Morelli P, Rovati S, Mautone G. Efficacy and safety of the Betamethasone valerate 0.1% plaster in mild-to-moderate chronic plaque psoriasis: a randomized, parallel-group, active-controlled, phase III study. Am J Clin Dermatol. 2011 Jun 1;12(3):191-201. doi: 10.2165/11539780-000000000-00000. PubMed PMID: 21284407. 14: Somuramasami J, Wei YC, Soliman EF, Rustum AM. Static headspace gas chromatographic method for the determination of low and high boiling residual solvents in Betamethasone valerate. J Pharm Biomed Anal. 2011 Jan 5;54(1):242-7. doi: 10.1016/j.jpba.2010.08.003. Epub 2010 Aug 13. PubMed PMID: 20828963. 15: Saraceno R, Chiricozzi A, Nisticò SP, Tiberti S, Chimenti S. An occlusive dressing containing betamethasone valerate 0.1% for the treatment of prurigo nodularis. J Dermatolog Treat. 2010 Nov;21(6):363-6. doi: 10.3109/09546630903386606. PubMed PMID: 20536273. 16: Vozza A, Di Girolamo F, Montesarchio G, Capuano A, Ascierto PA, Vozza G. Kerion Celsi favored by the use of a tretinoin+minoxidil+betamethasone valerate lotion in a 28-year-old woman. G Ital Dermatol Venereol. 2010 Apr;145(2):313-5. PubMed PMID: 20467404. 17: Thawornchaisit P, Harncharoen K. A comparative study of tar and betamethasone valerate in chronic plaque psoriasis: a study in Thailand. J Med Assoc Thai. 2007 Oct;90(10):1997-2002. PubMed PMID: 18041415. 18: Xhauflaire-Uhoda E, Thirion L, Piérard-Franchimont C, Piérard GE. Comparative effect of tacrolimus and betamethasone valerate on the passive sustainable hydration of the stratum corneum in atopic dermatitis. Dermatology. 2007;214(4):328-32. PubMed PMID: 17460405. 19: Hajheydari Z, Jamshidi M, Akbari J, Mohammadpour R. Combination of topical garlic gel and betamethasone valerate cream in the treatment of localized alopecia areata: a double-blind randomized controlled study. Indian J Dermatol Venereol Leprol. 2007 Jan-Feb;73(1):29-32. PubMed PMID: 17314444. 20: Kitsukawa S, Ito T, Hosoda S, Samejima T, Otsuru N, Matsumoto T, Yamamoto Y, Noda K, Matsumoto T, Aizawa T. [Early effect of non-surgical treatment using betamethasone valerate ointment for phimosis in childhood]. Hinyokika Kiyo. 2006 May;52(5):337-41. Japanese. PubMed PMID: 16758721.

View History

ATL-444

MedKoo CAT#: 145295

CAS#: 867054-13-5